** India's Divi's Laboratories DIVI.NS gains 5% to 6,228.50 rupees
** DIVI's proposed 18MT capacity and a fully integrated infrastructure for tirzeptide, the active ingredient for Lilly's blockbuster Mounjaro, will give DIVI a competitive edge over rivals, says Citi
** Brokerage hikes PT on active ingredients maker to 7,050 rupees from 6,850 rupees
** U.S. drugmaker Eli Lilly's LLY.N oral weight-loss drug orforglipron is the next addition to DIVI's pipeline, which is a "big one", says Citi
** Drugmaker has so far announced a capex of $170 mln, which CITI believes is primarily for GLP-1 class of weight-loss drugs
** DIVI second-biggest gainer on Nifty pharma index NIPHARM which is up 1.2%.
** Brokerage calls DIVI its "top pharma pick" and forecasts over $800 mln revenue by 2030 from GLP-1s
** Avg rating of 21 analysts on DIVI at "hold"; median PT is 5,737.50 rupees - data compiled by LSEG
** DIVI up 2% YTD vs pharma index's 6% decline
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))